Previous close | N/A |
YTD return | N/A |
Expense ratio (net) | N/A |
Category | N/A |
Last cap gain | N/A |
Morningstar rating | N/A |
Morningstar risk rating | N/A |
Sustainability rating | N/A |
Net assets | N/A |
Beta (5Y monthly) | N/A |
Yield | N/A |
5y average return | N/A |
Holdings turnover | N/A |
Last dividend | N/A |
Average for category | N/A |
Inception date | N/A |
Company announcement no. 04/2022 April 25, 2022 Please see attachment. For further information, please contact:Anders Mohr Christensen, Vice President Group Strategy & Investor Relations, Tel: +45 2515 2364Annika Stern, Senior Investor Relations Manager, Tel: +45 2399 2382Sanne Seyer-Hansen, Head of Media Relations, Tel: +45 6038 6207 About Chr. HansenChr. Hansen is a global, differentiated bioscience company that develops natural ingredient solutions for the food, nutritional, pharmaceutical an
Company announcement no. 03/2022 April 6, 2022 Strong Q2 growth in a challenging environment Statement by CEO Mauricio Graber: “In a challenging environment, Chr. Hansen continued its strong growth trajectory, delivering 14% organic growth in the second quarter. Growth in Health & Nutrition further accelerated, supported by Human Health, while Food Cultures & Enzymes showed solid growth, mainly driven by its core segments and developed markets. In the second quarter, the EBIT margin b.s.i. incre
January 13, 2022 Company announcement no. 1 Solid start to the year Statement by CEO Mauricio Graber: “The encouraging start to the year with organic growth of 9% and progress across all business areas and strategic initiatives underlines the strength of our 2025 strategy differentiating us as a bioscience company focused on microbial and fermentation technology platforms. Food Cultures & Enzymes continued its strong momentum in the first quarter, while Health & Nutrition delivered a strong reb